ClinicalTrials.gg
CompletedNCT05611606Updated Dec 5, 2022

Welfare Benefits in Functional Somatic Disorders

An observational study in Fibromyalgia, Irritable Bowel Syndrome and Chronic Fatigue Syndrome, sponsored by University of Aarhus. Completed. Open to participants aged 18 Years to 76 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by University of Aarhus · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
9,656
Ages
18 Years to 76 Years
Sex
All
01

Study summary

The objective of this observational study is to estimate the number of weeks of welfare benefits, i.e. sickness benefit, unemployment benefit and social assistance, for individuals with functional somatic disorders and compare them to

  1. healthy individuals, and
  2. individuals with severe physical disease.
Read the detailed description

Functional somatic disorders (FSD) are common conditions characterized by persistent patterns of physical symptoms that cannot be better explained by other physical or mental conditions (1). The conditions may cause severe impairment for the patients who present with reduced physical and mental health, lower social status, and poor labour market association (2-4).

In 2005, it was estimated that FSD accounted for 3% of hospitalizations and 10-20% of health care expenses in Denmark (5), and a newer Danish primary care study has shown patients with FSD to have higher annual health care costs compared with conventionally-defined conditions (6). In other countries, studies in clinical samples have shown increased direct and indirect health care costs of FSD (7, 8) showing a dose-response relationship with severity of the FSD (9). These studies into highly selected clinical samples may induce high risk of selection bias, and studies including random selected general population samples are therefore needed. One Canadian population-based study on health care costs of children, adolescents, and young adults with FSD also found increased health care use and costs for this group (10). Studies investigating the socioeconomic burden in terms of welfare benefits of FSD in an adult random sample from the general population are, however, lacking.

Objective To estimate the number of weeks of welfare benefits, i.e. sickness benefit, unemployment benefit and social assistance, for individuals with FSD and compare them to individuals without FSD and individuals with severe physical disease.

02

Conditions studied

  • Fibromyalgia
  • Irritable Bowel Syndrome
  • Chronic Fatigue Syndrome
  • Bodily Distress Syndrome
  • Somatoform Disorders
  • Medically Unexplained Syndrome
  • Medically Unexplained Symptoms
03

In context

Fibromyalgia

1,243 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

This study's enrollment of 9,656 is above the median of 100 across 279 observational studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,300 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants were randomly drawn from the adult general Danish population by means of the the Danish Civil Registration system.

The DanFunD baseline cohort comprises a total of 9,656 (33.7% of invited participants) men and women aged 18-76 years, born in Denmark, and living in the Western part of greater Copenhagen. All participants filled in questionnaires regarding physical symptoms and psychological factors, among others. A stratified subsample (n=2,450) of every tenth participant and every symptom high score participant on the DanFunD baseline symptom questionnaires were invited to participate in a diagnostic interview, the Research Interview for Functional somatic Disorders (RIFD), performed by trained family physicians (28); 1,590 (64.9%) accepted and participated in the interview.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • None

Exclusion criteria

Exclusion Criteria:

  • Not born in Denmark
  • Not being a Danish citizen
  • Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
9,656 participants (actual)
Patient registry
No

Groups and cohorts

  • DanFunD baseline

    Data from the DanFunD baseline cohort will be included (11). It comprises a total of 9,656 (33.7% of the invited participants) men and women aged 18-76 years born in Denmark and living in the Western part of greater Copenhagen. Individuals with FSD are identified by means of self-reported questionnaires (n=9,656) (2) and diagnostic research interviews (n=1,590) (12). Participants with FSD will be defined as follows: * FSD operationalised by the Bodily Distress Syndrome single- and multi-organ type will be defined with both self-reported questionnaires (14) and diagnostic interviews (3) * Three functional somatic syndromes, i.e. irritable bowel (15), chronic widespread pain (16), and chronic fatigue (17) will be defined with questionnaires. Severe physical disease will be defined as having received at least one of the following five diagnoses: Cancer, stroke, myocardial infarction, other heart disease, and obstructive pulmonary disease.

06

What researchers measure

Primary outcomes

  1. Sickness benefit

    Wellfare benefit disbursed to employed citizens being ill, unemployed citizens currently ill, citizens in activation programs currently ill, and citizens in flexible jobs but currently ill

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

  2. Unemployment benefit

    Welfare benefit disbursed to unemployed citizens who receive unemployment benefit (full or part time, during vacation or activation) together with citizens on social assistance who are deemed ready-to-work, only receiving social assistance because of unemployment, but having no entitlement to unemployment benefit.

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

  3. Social assistance

    A welfare payment administered by the municipal social service department and is allocated if citizens are unable to support themselves.

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

Secondary outcomes

  1. No transfer income/self-support

    Individuals that do not receive welfare payments under the circumstances of sickness, unemployment, or social benefits. Including leave-of-absence schemes and grants from State Education Fund.

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

  2. Public retirement pension

    Public retirement pension

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

  3. Emigration

    Participant not resident in Denmark

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

  4. Death

    Participant dead

    Time frame: 10-year period before and 5-year period after the day the participant participated in the DanFunD baseline investigation

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05611606
Collaborators
Center for Clinical Research and Prevention
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
Nov 10, 2011
Primary completion
Jun 30, 2015
Completion
Aug 30, 2015
Last update
Dec 5, 2022

Study contacts

Per Fink, DMSc
study chair · Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion